- China May Cut Taxes to Aid Light Industry
- Elpida, Taiwanese Chipmakers to Integrate
- Australia Consumers Fearful Despite Stimulus
- AIG May Sell Auto Unit to Insurer Zurich
- Australia's CBA May Cut Dividend as First-Half Falls
- Asian Stocks Slide as US Rescue Plan Disappoints
- Sirius XM Prepares Possible Bankruptcy Filing
- Nvidia Results Miss Estimates; Shares Fall
- Applied Materials Reports Sharply Lower Results
- Cramer’s Outrage: Principal Financial Group
- Lightning Round OT: Goldman Sachs, Carnival and More
- A Sector Geithner Can’t Touch?
- Mary Schapiro’s To-Do List
- Cramer Finds Good in Geithner Plan
- Your First Move For Wednesday February 11th
- Web Extra: Fast & Furious Trades For Wednesday
- Rising Star Stock – Monday February 9th
- Range Roving with Jon Najarian
- Mayor: Obama should apologize for Vegas trips quip
- Press corps in DC more specialized, international
- Canada court stops Rusoro takeover of Gold Reserve
- Saudi oil minister warns of volatile markets
- Canadian regulator says TV profits down
- Examiner to investigate sale of club for megarich
- US Airways cutting 233 ramp and ticket workers
- Credit markets just part fixing economic puzzle
- Toy makers not playing around in downturn
BOSTON - Medical device maker NeuroMetrix Inc. will pay $3.7 million to settle a federal investigation of its sales and marketing of a diagnostic test for nerve conditions.
The U.S. Attorney's office on Monday said the Waltham-based company has accepted responsibility for illegally giving physicians free accessories for its NC-stat system to encourage them to press colleagues to buy the device.
NeuroMetrix said it agreed to pay a criminal penalty of $1.2 million and pledged to change its business practices. The company will not be prosecuted if it observes terms of the deal over the next three years.
NeuroMetrix also agreed to pay $2.5 million in civil damages and penalties for the kickbacks and to settle charges that it caused physicians to improperly bill Medicare.
NeuroMetrix has entered into a five-year Corporate Integrity Agreement with federal officials and says it remains eligible to participate in all federal health care programs.


